Has Lawrence Reccoppa received payments from drug or device companies?

Yes. Drug and device makers reported $968,069 in general payments to Lawrence Reccoppa across 1,441 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lawrence Reccoppa did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lawrence Reccoppa come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lawrence Reccoppa

Psychiatry · Gainesville, FLNPI 1215095534

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $776,443 of the $968,069 with a category attached, or 80.2%. 13 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 39.9% of the total. 2025 is the largest year on record at $339,445, 2.7 times the $125,714 reported in 2019. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$968,069in general payments, 2019–2025

Across 1,441 payments — averaging $671.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386K
Vanda Pharmaceuticals Inc.$210K
Alkermes, Inc.$135K
E.r. Squibb & Sons, L.L.C.$123K
Sunovion Pharmaceuticals Inc.$69K
Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
plus $20K from 7 others

What the payments were for

Consulting fees$38,1094%
Speaking & faculty fees$776,44380%
Travel & lodging$120,15312%
Food & beverage$33,3223%
Education$420%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	577	$385,813
Vanda Pharmaceuticals Inc.	320	$209,710
Alkermes, Inc.	174	$135,232
E.r. Squibb & Sons, L.L.C.	161	$122,746
Sunovion Pharmaceuticals Inc.	106	$68,676
Otsuka Pharmaceutical Development & Commercialization, Inc.	29	$25,637
AbbVie(2 entities)	21	$10,645
Supernus Pharmaceuticals, Inc.	18	$8,411
Teva Pharmaceuticals USA, Inc.	15	$538
Neurocrine Biosciences, Inc.	9	$359
Otsuka America Pharmaceutical, Inc.	4	$160
Johnson & Johnson	5	$97
Axsome Therapeutics, Inc.	2	$46

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ARISTADA$419,617
CAPLYTA$375,656
Fanapt$204,689
LYBALVI$108,908
ARISTADA INITIO$104,904
COBENFY$77,850
LATUDA$66,735
VRAYLAR$10,227
QELBREE$5,612
Austedo XR$232
INGREZZA$122
REXULTI$102

How this compares

$968,069 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	13	$41,658
Quetiapine Fumarate	14	$204
Trazodone Hcl	17	$135
Buspirone Hcl	12	$129
Hydroxyzine Pamoate	13	$103
Clonazepam	12	$101
Risperidone	11	$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Sustenna	$97	$41,65813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Gainesville

Mathew NguyenGainesville$110K
Andrew CutlerLakewood Ranch$5.7M
Richard JacksonBoca Raton$3.6M
Ilan MelnickCoral Gables$2.8M
Todd BroderSt Augustine$1.6M
Heather LuingSaint Augustine$1.5M
Todd GatesWest Melbourne$1.2M
Thomas ValenteLeesburg$967K
Michelle ScargleClearwater$926K
David SheehanTampa$631K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →